PriceTargets.com logo

CervoMed - CRVO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.60
  • Forecasted Upside: 397.68%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$10.77 As of 11/15/2024 01:00 AM ET
▼ -0.15 (-1.37%)

This chart shows the closing price for CRVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CervoMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRVO

Analyst Price Target is $53.60
▲ +397.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CervoMed in the last 3 months. The average price target is $53.60, with a high forecast of $65.00 and a low forecast of $35.00. The average price target represents a 397.68% upside from the last price of $10.77.

This chart shows the closing price for CRVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in CervoMed.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
9/18/2024Chardan CapitalInitiated CoverageBuy$55.00
7/26/2024Morgan StanleyInitiated CoverageOverweight$35.00
7/25/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
7/8/2024Brookline Capital ManagementInitiated CoverageBuy$63.00
4/8/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$50.00 ➝ $65.00
2/15/2024Canaccord Genuity GroupInitiated CoverageBuy$50.00
2/15/2024Canaccord Genuity GroupInitiated CoverageBuy$50.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CervoMed logo
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.77
Low: $10.46
High: $11.29

50 Day Range

MA: $13.92
Low: $10.77
High: $17.51

52 Week Range

Now: $10.77
Low: $5.85
High: $26.38

Volume

67,468 shs

Average Volume

80,178 shs

Market Capitalization

$66.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of CervoMed?

The following sell-side analysts have issued research reports on CervoMed in the last year: Brookline Capital Management, Canaccord Genuity Group Inc., Chardan Capital, and Morgan Stanley.
View the latest analyst ratings for CRVO.

What is the current price target for CervoMed?

0 Wall Street analysts have set twelve-month price targets for CervoMed in the last year. Their average twelve-month price target is $53.60, suggesting a possible upside of 397.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting CRVO will reach $65.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $35.00 for CervoMed in the next year.
View the latest price targets for CRVO.

What is the current consensus analyst rating for CervoMed?

CervoMed currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRVO will outperform the market and that investors should add to their positions of CervoMed.
View the latest ratings for CRVO.

What other companies compete with CervoMed?

Other companies that are similar to CervoMed include Eton Pharmaceuticals, Pyxis Oncology, Zentalis Pharmaceuticals, Atyr PHARMA and Sutro Biopharma. Learn More about companies similar to CervoMed.

How do I contact CervoMed's investor relations team?

CervoMed's physical mailing address is 2020 Avon Ct Ste 4, Charlottesville, Virginia 22902-8734. The company's listed phone number is 14342200718 and its investor relations email address is [email protected]. The official website for CervoMed is diffusionpharma.com. Learn More about contacing CervoMed investor relations.